Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV-2 Infection

S Stagnoli, G Macari, P Corsi, B Capone… - ACS …, 2023 - ACS Publications
The urgency to find complementary therapies to current SARS-CoV-2 vaccines, whose
effectiveness is preserved over time and not compromised by the emergence of new and …

Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV-2 Infection.

S Stagnoli, G Macari, P Corsi, B Capone… - ACS Omega, 2023 - europepmc.org
The urgency to find complementary therapies to current SARS-CoV-2 vaccines, whose
effectiveness is preserved over time and not compromised by the emergence of new and …

Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV-2 Infection

S Stagnoli, G Macari, P Corsi, B Capone… - ACS …, 2023 - pubmed.ncbi.nlm.nih.gov
The urgency to find complementary therapies to current SARS-CoV-2 vaccines, whose
effectiveness is preserved over time and not compromised by the emergence of new and …

[PDF][PDF] Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV‑2 Infection

2023 - scienceopen.com
The urgency to find complementary therapies to current SARS-CoV-2 vaccines, whose
effectiveness is preserved over time and not compromised by the emergence of new and …

[HTML][HTML] Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV-2 Infection

S Stagnoli, G Macari, P Corsi, B Capone… - ACS Omega, 2023 - ncbi.nlm.nih.gov
The urgency to find complementary therapies to current SARS-CoV-2 vaccines, whose
effectiveness is preserved over time and not compromised by the emergence of new and …